Novavax Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights - Novavax Investor Relations

2/28/2022 12:00:00 AM3 years 2 months ago

NVX-CoV2373 is the first protein-based COVID-19 vaccine authorized in multiple major markets around the world, including the European Union, Australia, Canada, and Great Britain; authorizations...

GAITHERSBURG, Md., Feb. 28, 2022 /PRNewswire/ --

  • NVX-CoV2373 is the first protein-based COVID-19 vaccine authorized in multiple major markets around the world, including the European Union,… [+20452 chars]

    full article...